Starget Pharma designs radioactive drugs that hunt tumors and spare healthy tissue
The Series A biotech, founded by alumni of Nasdaq-listed UroGen Pharma, is one of 23 startups selected for ScaleUp House's inaugural cohort.
Starget Pharma is one of the companies selected for the inaugural ScaleUp House cohort, joining the year-round program as it enters its next stage of international growth. The company develops AI-designed peptide radioligands that home to tumors and deliver targeted radiation for metastatic cancers, with a focus on expanding its presence in global markets and building the foundations for its next phase of growth.
ID card
- Name: Starget Pharma
- Industry: Pharma / BioTech
- Current Stage: A
- Founder Name: Sigalit Kalmanson Cusnir
- Year Founded: 2019
- Number of Employees: 21
Company Description
Starget Pharma develops Smart Targeted Radioligands (STRs) for metastatic cancers. Its AI-driven platform designs peptide radioligands that home to tumors and deliver high-energy radiation inside cancer cells, sparing healthy tissue. Backed by $40M+ and founders of UroGen Pharma (NASDAQ: URGN), leadership spans peptide engineering, AI, and nuclear medicine, with three radioligand candidates entering clinical trials in 2026 across breast, sarcoma and prostate cancers.
